Defining the research priorities to fight the burden of cardiovascular diseases in Latin America

Journal of Hypertension

Volumn 26, Issue 9, 2008, Pages 1886-1889

  Lopez Jaramillo, Patricio ^a,b,c  

^a Research Institute   (Colombia)

^b UNIVERSIDAD DE SANTANDER   (Colombia)

^c FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; GLUCOSE TOLERANCE TEST; HEART RATE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIORITY JOURNAL; RESEARCH PRIORITY; SOUTH AND CENTRAL AMERICA; SYSTOLIC BLOOD PRESSURE; PREVALENCE; RESEARCH; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; LATIN AMERICA; PREVALENCE; RESEARCH; RISK FACTORS;

EID: 58149267950     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328308ba8d     Document Type: Note

References (34)

1. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, Massachusetts: Harvard School of Public Health; 1996.
2. Murray CJ, Lopez AD. Global mortality, disability, and thecontribution ofrisk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-1442.
3. Lopez-Jaramillo P, Casas JP, Bautista L, Serrano NC, Morillo CA. An integrated proposal to explain the epidemic of cardiovascular disease in a developing country. From socioeconomic factors to free radicals. Cardiology 2001; 96:1 -6.
4. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Latin America. Nutr Rev 2001; 59:170-176.
5. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002; 288:1728-1732.
6. Hales C, Barker D. Type 2 (noninsulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35:595-601.
7. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev 2005; 85:571 -633.
8. Ravelli A, van der Meulen J, Osmond C, Barker D, Bleker O. Obesity atthe age of50 years in men and women exposed to famine prenatally. Am JClin Nutr 1999; 70:811-816.
9. Painter RC, de Rooij SR, Bossuyt PM, et al. Early onset of coronary artery disease after prenatal exposure to Dutch famine. Am J Clin Nutr 2006; 84:322-327.
10. De Rooij SR, Painter RC, Roseboom TJ, et al. Glucose tolerance at age 59 and the decline of glucose tolerance in comparison with age 50 in people prenatally exposed to the Dutch famine. Diabetologia 2006; 49:637-643.
11. Waterland RA, Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999; 69:179-197.
12. Gallou-Kabani C, Junien C. Nutritional epigenomics ofmetabolicsyndrome. New perspective against the epidemic. Diabetes 2005; 54:1899 -1906.
13. Lopez-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. Socioeconomic pathology as a cause of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol 2007; 60:168-178.
14. Lopez-Jaramillo P, Silva SY, Rodriguez-Salamanca N, Duran A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases? Am J Therapeut 15(in press).
15. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with AMI in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
16. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, Yusuf S, INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007; 115:1067-1074.
17. Kabagambe EK, Baylin A, Campos H. Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population-attributable risks, and adherence to dietary guidelines. Circulation 2007; 115:1075-1081.
18. Lopez-Jaramillo P, Herrera E, Garcia R, Camacho PA, Castillo V. Inter relationship of body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am JHypertens 2008; 21:527-532.
19. Ford ES. C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2003; 108:1053-1058.
20. Gillum RF. Association of serum C-reactive protein and indices of body fat distribution and overweight in Mexican American children. J Natl Med Assoc 2003; 95:545-552.
21. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics 2001; 107:E13.
22. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, etal. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000; 149:139-150.
23. Aeberli I, Molinari L, Spinas G, Lehmann R, l'Allemand D, Zimmermann MB. Dietary intakes of fat and antioxidant vitamins are predictors of subclinical inflammation in overweight Swiss children. Am J Clin Nutr 2006; 84:748-755.
24. Weiss R, Dziura J, BurgertTS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
25. Perez M, Casas JP, Cubillos-Garzon LA, Serrano NC, Silva F, Morillo CA, Lopez-Jaramillo P. Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2003; 10:328-335.
26. Bautista L, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independentrisk factor for essential hypertension? J Hypertens 2001; 19:857-861.
27. Garcia RG, Perez M, Maas R, Schwedhelm E, Böger RH, Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007; 122:176-178.
28. Lear SA, Chen MM, Birmingham L, Frohlich JJ. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism 2003; 52:1542-1546.
29. KheraA, McGuireDK, MurphySA, StanekHG, DasSR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46:464-469.
30. Lambert M, Delvin EE, Paradis G, O'Loughlin J, Hanley JA, Levy E. C-reactive protein and features of the metabolic syndrome in a population- based sample of children and adolescents. Clin Chem 2004; 50:1762-1768.
31. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne- Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
32. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 2002; 346:393-403.
33. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. Indian Diabetes Prevention Programme (IDPP). The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289-297.
34. Alderman MH, Ogihara T. Global challenge for overcoming high blood pressure: Fukuoka Statement, 19 October 2006. J Hypertens 2007; 25:727.